While novel therapies have been in development to specifically address defects resulting from dystrophin deficiency, their effectiveness with respect to cardiac function has been limited due to the diverse range of genetic mutations in DMD and the complex risks of each prospective therapy (reviewed in [92]). This evidence concerns the gene DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.